Introduction
Antimicrobial peptides (AMPs) are widely distributed in nature, generally have broad-spectrum activity and represent a promising class of new antimicrobial agents. However, it is widely accepted that native AMPs lack specificity and may be too toxic (ability to lyse mammalian cells, normally expressed as hemolytic activity against human red blood cells) to be used for systemic treatment [1, 2] . To overcome this problem, we developed the design concept of "specificity determinants" which refers to substituting positively charged residue(s) in the center of the non-polar face of amphipathic cyclic β-sheet [3, 4] or amphipathic α-helical AMPs [5] to create selectivity between eukaryotic and prokaryotic membranes; that is, antimicrobial activity is improved or maintained and hemolytic activity or cell toxicity to mammalian cells is decreased or eliminated. We showed that a single valine to lysine substitution in the center of the non-polar face of an AMP dramatically reduced toxicity and increased the therapeutic index [5] [6] [7] .
The question arose could we take such a broad spectrum AMP in the all-D conformation and use a rational design approach to enhance further the biological properties if the focus was to develop a better Gram-negative AMP rather than maintain broad-spectrum activity. Our final AMP had a 746-fold improvement (i.e., decrease) in its hemolytic activity, improved antimicrobial activity and improved therapeutic indices by 1305-fold and 895-fold against Acinetobacter baumannii and Pseudomonas aeruginosa, respectively [7] . We applied this design concept to native AMPs, piscidin 1 (isolated from mast cells of hybrid striped bass -Morone saxatilis male × Morone chrysops female) and dermaseptin S4 (isolated from the skin of tree-dwelling, South American frogs of the Phyllomedusa species), where substitution of one or two lysine residues at different positions in their non-polar faces enhanced or maintained Gram-negative activity, dramatically decreased hemolytic activity and significantly improved the therapeutic indices (55-fold and 730-fold for D-piscidin 1 I9K and D-dermaseptin S4 L7K, A14K against A. baumannii, respectively) [8] .
In the current study, we used the above 2 native AMPs and tested their activity against 2 different pathogens: 11 and 20 diverse clinical isolates of A. baumannii, and Staphylococcus aureus (12 Methicillin-sensitive S. aureus strains and 8 Methicillin/Oxacillin-resistant S. aureus strains), respectively. We showed that substitution of "specificity determinant(s)" in broad spectrum AMPs, encode selectivity for Gram-negative pathogens and simultaneously remove both Gram-positive activity and hemolytic activity of these 2 diverse amphipathic α-helical AMPs which differ dramatically in amino acid composition, net positive charge and amphipathicity, showing generality of our approach.
Results and Discussion
The peptide analogs (D-piscidin 1, D-piscidin 1 I9K, D-dermaseptin S4 and D-dermaseptin S4 L7K, A14K) ( Figure 1 ) were synthesized by standard solid-phase peptide synthesis methodology using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry on Rink amide 4-methylbenzhydrylamine resin using a CEM Liberty microwave peptide synthesizer and using Boc-chemistry on 4-methylbenzhydrylamine (MBHA) solid support. Peptides were cleaved from the resins by TFA cleavage cocktail for Fmoc chemistry or by HF for Boc chemistry. Peptide purification was performed by reversed-phase highperformance liquid chromatography (RP-HPLC) on a Zorbax 300 SB-C8 column (250 × 9.4 mm I.D.; 6.5 µm particle size, 300 Å pore size; Agilent Technologies, Little Falls, DE, USA). The minimal inhibitory concentration (MIC) was measured by a standard microtiter two-fold serial dilution method in Mueller Hinton (MH) medium after incubation at 37°C for 24h. The hemolytic activity was determined as the peptide concentration that caused 50% hemolysis (compared to human erythrocytes treated with water or 0.1% Triton-X 100 as 100% lysis) of erythrocytes after 18h (HC50). Antibacterial activities against 11 strains of A. baumannii and 20 strains of S. aureus are compared in Tables 1 and 2 , respectively. Geometric mean of MIC values was calculated to provide an overall view of antibacterial activity of different analogs. It is clear that all four of our peptides were effective in killing Gram-negative pathogen A. baumannii. The single specificity determinant analog (D-piscidin 1 I9K) and D-dermaseptin S4 L7K, A14K with two specificity determinants exhibited similar or improved antibacterial activity compared to their parent peptides: D-piscidin 1 and D-dermaseptin S4 (Table 1) . However, the new analogs have a dramatic decrease in antibacterial activity against Grampositive pathogen S. aureus ( Table 2) . As summarized in Table 3 , a single "specificity determinant" had a dramatic effect in lowering the hemolytic activity of D-piscidin 1 from a HC50 value of 1.8 µM to 98 µM for D-piscidin 1 I9K, a 54-fold improvement (Table 3 ). In addition, two "specificity determinants" in D-dermaseptin S4 gave the analog D-dermaseptin S4 L7K, A14K which decreased hemolytic activity from 0.6 µM to a HC50 value of 241 µM, a 402-fold improvement in hemolytic activity (Table 3) . The corresponding therapeutic indices when comparing hemolytic activity and antimicrobial activity against A. baumannii showed a dramatic improvement of 55-fold and 730-fold, respectively (Table 3) .
However, the antibacterial activity against the Gram-positive pathogen S. aureus was lost. The new peptide analogs turned into Gram-negative pathogen-selective AMPs with a Gram-negative selectivity factor of 60 for D-piscidin 1 I9K and >319 for D-dermaseptin S4 L7K, A14K (Table 3) . In summary, we have taken two examples of native AMPs, piscidin 1 and dermaseptin S4, to demonstrate the universality of our "specificity determinant" design concept to effect a dramatic reduction in AMP hemolytic activity and antibacterial activity against the Gram-positive pathogen S. aureus, while maintaining or improving antibacterial activity against Gram-negative pathogen A. baumannii to successfully generate Gram-negative pathogen-selective AMPs as potential drug candidates. To us, the excitement in the field of amphipathic α-helical AMPs lies in our demonstration that a single or double substitution in nature's AMP sequences can have such a dramatic effect on changing their biological profiles for drug development.
